Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2256 articles about Gilead Sciences, Inc.
-
Two Upstarts that Could Dislodge Gilead's Hold on the Hepatitis C Market
6/22/2016
-
5 Biotech Stocks at Bargain Basement Prices
6/22/2016
-
Gilead Presents Preliminary Data On Bictegravir, An Investigational Integrase Strand Transfer Inhibitor For The Treatment Of HIV
6/20/2016
-
Gilead To Present At The 36th Annual William Blair Growth Stock Conference On Tuesday, June 14
6/14/2016
-
Gilead To Present At The Jefferies 2016 Healthcare Conference On Friday, June 10
6/10/2016
-
Days After Judge Overturns Merck & Co.-Gilead Lawsuit, Merck Acquires Bay Area's Afferent Pharma for $1.2 Billion
6/10/2016
-
Federal Judge Reverses Merck & Co.’s $200 Million Patent Win Against Gilead Over False Testimony
6/9/2016
-
New Gilead CEO's Game Plan to Maintain HCV Dominance
6/8/2016
-
Gilead To Present At The Goldman, Sachs & Co. 37th Annual Global Healthcare Conference On Wednesday, June 8
6/8/2016
-
3 Bargain Pharma Stocks to Watch
6/7/2016
-
Lawsuit Claims Gilead Could Have Created Safer HIV Drug Sooner But Didn't Due to Profits
5/31/2016
-
Gilead, Biogen, Jazz Pharma Subpoenaed as Feds Investigate Drugmaker-Charity Connections
5/27/2016
-
European CHMP Adopts Positive Opinion For Gilead’s Epclusa(Sofosbuvir/Velpatasvir) For The Treatment Of All Genotypes Of Chronic Hepatitis C
5/27/2016
-
Retired Gilead Exec Returns as His Replacement Exits
5/26/2016
-
Nine Bay Area Biotechs Vie to be the “Next Genentech”
5/26/2016
-
Count Celgene and Gilead as New Suitors to Acquire the Popular Medivation
5/26/2016
-
Gilead To Present At The UBS Global Healthcare Conference On Monday, May 23
5/23/2016
-
Nimbus Therapeutics Announces Closing Of Gilead’ Acquisition Of Nimbus Apollo, Inc., And Its Acetyl-CoA Carboxylase (ACC) Inhibitor Program
5/17/2016
-
Gilead Elated as India Upholds Sovaldi Patent
5/11/2016
-
Gilead To Present At The Bank of America Merrill Lynch Healthcare Conference On Tuesday, May 10
5/10/2016